Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) EBIT: 2012-2024

Historic EBIT for BioLineRx (BLRX) over the last 13 years, with Dec 2024 value amounting to -$20.4 million.

  • BioLineRx's EBIT rose 60.11% to -$2.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$14.5 million, marking a year-over-year increase of 65.06%. This contributed to the annual value of -$20.4 million for FY2024, which is 58.93% up from last year.
  • BioLineRx's EBIT amounted to -$20.4 million in FY2024, which was up 58.93% from -$49.7 million recorded in FY2023.
  • Over the past 5 years, BioLineRx's EBIT peaked at -$20.4 million during FY2024, and registered a low of -$49.7 million during FY2023.
  • Its 3-year average for EBIT is -$33.1 million, with a median of -$29.2 million in 2022.
  • Per our database at Business Quant, BioLineRx's EBIT slumped by 70.44% in 2023 and then skyrocketed by 58.93% in 2024.
  • Over the past 5 years, BioLineRx's EBIT (Yearly) stood at -$22.9 million in 2020, then decreased by 8.07% to -$24.8 million in 2021, then declined by 17.68% to -$29.2 million in 2022, then slumped by 70.44% to -$49.7 million in 2023, then skyrocketed by 58.93% to -$20.4 million in 2024.